Driving Transformation by Bringing Together Diverse Knowledge
First written in FY2018-Q1. 11 of 21 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026ReframedAnnual report
「Under the medium-term management plan “Vision 110 －Stage 2－,” the statement is “Proactive investment for sustainable growth.” The company positions the acquisition of in-licensed products and other assets that will serve as long-term growth engines as its top priority and is pursuing this objective with firm conviction.」
The management policy was changed from “Establishing a business structure for realizing Vision 110” in Stage1 to “Proactive investment for sustainable growth” in Stage2, with the acquisition of in-licensed products and other assets as the top priority. - FY2026-H1ReframedAnnual report
「For the fiscal year ending March 2026, the final year of Stage1, the company adopted “Establishing a business structure for realizing Vision 110” as its management policy and is working to achieve its goals.」
The management policy for the final year of Vision 110 Stage1 was changed from “Achieving transformation” in the previous fiscal year to “Establishing a business structure for realizing Vision 110.” - FY2025-H1ReframedAnnual report
「In the fiscal year ending March 2025, the second year of the plan, the company adopted “Achieving transformation” as its management policy and is actively pursuing ① achieving transformation in drug discovery, ② expanding its pipeline, ③ maximizing the uptake of new drugs, and ④ improving cost competitiveness, among other initiatives.」
The management policy for the second year of Vision 110 Stage1 was changed from “Growth through renewal of the business structure and new initiatives” in the previous fiscal year to “Achieving transformation.” - FY2024-Q3RestatedAnnual report
「In the fiscal year ending March 2024, the first year of the plan, the company adopted “Growth through renewal of the business structure and new initiatives” as its management policy and is actively pursuing ① renewal of its drug discovery organization, ② expansion of its pipeline, ③ maximizing the uptake of new drugs, and ④ improving cost competitiveness as business activities.」
The company continues to pursue the management policy and 4 key business activities for the first year of Vision 110 Stage1. - FY2024-Q2RestatedAnnual report
「In the fiscal year ending March 2024, the first year of the plan, the company adopted “Growth through renewal of the business structure and new initiatives” as its management policy and is actively pursuing ① renewal of its drug discovery organization, ② expansion of its pipeline, ③ maximizing the uptake of new drugs, and ④ improving cost competitiveness as key business activities.」
The company continues to pursue the management policy “Growth through renewal of the business structure and new initiatives” and 4 activity priorities for the first year of Vision 110 Stage1. - FY2024-Q1ReframedAnnual report
「In the fiscal year ending March 2024, the first year of the plan, the company adopted “Growth through renewal of the business structure and new initiatives” as its management policy,」
The company changed from its previous annual management policies to adopting “Growth through renewal of the business structure and new initiatives” for the first year of Vision 110－Stage1－. - FY2023-Q1ReframedAnnual report
「Under the FY2023 management policy “Achieving a growth trend through the pursuit of originality,” we focused on increasing business speed as a key point of our business strategy and actively pursued (1) faster growth of our new-medicine portfolio, (2) expansion of the development pipeline, and (3) faster drug discovery.」
The management policy was changed from “Discernment” in the previous fiscal year to “Realizing a growth trend through the pursuit of originality,” with business acceleration being pursued through 3 priority initiatives. - FY2022-Q2RestatedAnnual report
「Under the FY2022 management policy “Discernment in pursuing originality,” we actively pursued faster growth of our new-medicine portfolio, expansion of the development pipeline, faster drug discovery, and stronger cost competitiveness.」
The company continues to pursue the management policy “Pursuing originality through ‘discernment’” and 4 priority initiatives for the fiscal year ending March 2022. - FY2022-Q1ReframedAnnual report
「Under the FY2022 management policy “Discernment in pursuing originality,” we actively pursued faster growth of our new-medicine portfolio, expansion of the development pipeline, faster drug discovery, and stronger cost competitiveness.」
The wording of the management policy was changed from “Taking on challenges to pursue originality” in the previous fiscal year to “Discernment” for the fiscal year ending March 2022, with accelerating drug discovery added as a priority initiative. - FY2021-Q3RestatedAnnual report
「Under the FY2021 management policy “Taking on the challenge of pursuing originality,” we are working on faster growth of our new-medicine portfolio, expansion of the development pipeline and drug-discovery projects, and stronger cost competitiveness as our business strategies.」
The company continues to pursue the management policy and business strategy for the first year of Stage 3. - FY2021-Q1ReframedAnnual report
「In the fiscal year ended March 2021, the first year of the plan, the company operated under the management policy “Taking on challenges to pursue originality,”」
The management policy was changed from “Executing transformation by demonstrating the strength to see things through” in the previous fiscal year to “Taking on challenges to pursue originality” for the fiscal year ending March 2021. - FY2020-Q3RestatedAnnual report
「The Group has adopted “Executing transformation by demonstrating the strength to see things through” as its management policy, maintains a mindset of never giving up until the end, and is working with maximum focus on achieving its goals and securing a growth trajectory toward sustainable growth.」
The company continues to uphold “Executing transformation by demonstrating the strength to see things through” as its management policy for fiscal 2019. - FY2020-Q1ReframedAnnual report
「The Group has adopted “Executing transformation by demonstrating the strength to see things through” as its management policy, maintains a mindset of never giving up until the end, and is working with maximum focus on achieving its goals and securing a growth trajectory toward sustainable growth.」
The management policy was changed from “Executing transformation with speed” in the previous fiscal year to “Executing transformation by demonstrating the strength to see things through” for fiscal 2019. - FY2019RestatedAnnual report
「For fiscal 2018, the company adopted “Executing transformation with speed” as its management policy and worked to strengthen its growth platform and improve profitability.」
The company reaffirmed in its explanation of annual results that it had adopted “Executing transformation with speed” as its management policy for fiscal 2018. - FY2019-Q3RestatedAnnual report
「For fiscal 2018, the company adopted “Executing transformation with speed” as its management policy and is working to strengthen its growth platform and improve profitability.」
The company continues to uphold “Executing transformation with speed” as its management policy for fiscal 2018. - FY2019-Q2RestatedAnnual report
「For fiscal 2018, the company adopted “Executing transformation with speed” as its management policy and is working to strengthen its growth platform and improve profitability.」
The company continues to uphold “Executing transformation with speed” as its management policy for fiscal 2018. - FY2019-Q1ReframedAnnual report
「For fiscal 2018, the company adopted “Executing transformation with speed” as its management policy and is working to strengthen its growth platform and improve profitability.」
The management policy was changed from “Driving transformation by bringing together diverse expertise” in the previous fiscal year to “Executing transformation with speed” for fiscal 2018. - FY2018RestatedAnnual report
「For FY2017, we adopted “Driving transformation by bringing together diverse knowledge” as our management policy.」
The company continues to uphold its management policy for fiscal 2017 in its explanation of annual results. - FY2018-Q3RestatedAnnual report
「For FY2017, we adopted “Driving transformation by bringing together diverse knowledge” as our management policy.」
The company continues to uphold its management policy for fiscal 2017. - FY2018-Q2RestatedAnnual report
「For FY2017, we adopted “Driving transformation by bringing together diverse knowledge” as our management policy.」
The company continues to uphold its management policy for fiscal 2017. - FY2018-Q1First statedAnnual report
「For FY2017, we adopted “Driving transformation by bringing together diverse knowledge” as our management policy.」
Driving transformation by bringing together diverse knowledge was adopted as the management policy for FY2017.